These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 31215265)

  • 1. The potential of circulating cell free RNA as a biomarker in cancer.
    Cheung KWE; Choi SR; Lee LTC; Lee NLE; Tsang HF; Cheng YT; Cho WCS; Wong EYL; Wong SCC
    Expert Rev Mol Diagn; 2019 Jul; 19(7):579-590. PubMed ID: 31215265
    [No Abstract]   [Full Text] [Related]  

  • 2. The potential of circulating cell-free RNA as a cancer biomarker: challenges and opportunities.
    Zaporozhchenko IA; Ponomaryova AA; Rykova EY; Laktionov PP
    Expert Rev Mol Diagn; 2018 Feb; 18(2):133-145. PubMed ID: 29307231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-coding RNAs as biomarkers in liquid biopsies with a special emphasis on extracellular vesicles in urological malignancies.
    Zeuschner P; Linxweiler J; Junker K
    Expert Rev Mol Diagn; 2020 Feb; 20(2):151-167. PubMed ID: 31499007
    [No Abstract]   [Full Text] [Related]  

  • 4. Measurements Methods for the Development of MicroRNA-Based Tests for Cancer Diagnosis.
    Precazzini F; Detassis S; Imperatori AS; Denti MA; Campomenosi P
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33503982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of emerging biomarkers in prostate cancer liquid biopsies.
    Boerrigter E; Groen LN; Van Erp NP; Verhaegh GW; Schalken JA
    Expert Rev Mol Diagn; 2020 Feb; 20(2):219-230. PubMed ID: 31577907
    [No Abstract]   [Full Text] [Related]  

  • 6. RNA biomarkers from proximal liquid biopsy for diagnosis of ovarian cancer.
    Hulstaert E; Levanon K; Morlion A; Van Aelst S; Christidis AA; Zamar R; Anckaert J; Verniers K; Bahar-Shany K; Sapoznik S; Vandesompele J; Mestdagh P
    Neoplasia; 2022 Feb; 24(2):155-164. PubMed ID: 34998206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential of circulating exosomal RNA biomarkers in cancer.
    Chu YL; Li H; Ng PLA; Kong ST; Zhang H; Lin Y; Tai WCS; Yu ACS; Yim AKY; Tsang HF; Cho WCS; Wong SCC
    Expert Rev Mol Diagn; 2020 Jul; 20(7):665-678. PubMed ID: 32188269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on urine as a biomarker in cancer: a necessary review of an old story.
    Zhang W; Zhang XJ; Chao SY; Chen SJ; Zhang ZJ; Zhao J; Lv YN; Yao JJ; Bai YY
    Expert Rev Mol Diagn; 2020 May; 20(5):477-488. PubMed ID: 32212972
    [No Abstract]   [Full Text] [Related]  

  • 9. Integrated analysis of circulating cell free nucleic acids for cancer genotyping and immune phenotyping of tumor microenvironment.
    Chaddha M; Rai H; Gupta R; Thakral D
    Front Genet; 2023; 14():1138625. PubMed ID: 37091783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid Biopsy beyond Circulating Tumor Cells and Cell-Free DNA.
    Junqueira-Neto S; Batista IA; Costa JL; Melo SA
    Acta Cytol; 2019; 63(6):479-488. PubMed ID: 30783027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers.
    Lopez-Beltran A; Cheng L; Gevaert T; Blanca A; Cimadamore A; Santoni M; Massari F; Scarpelli M; Raspollini MR; Montironi R
    Expert Rev Mol Diagn; 2020 Feb; 20(2):231-243. PubMed ID: 31795775
    [No Abstract]   [Full Text] [Related]  

  • 12. Circulating RNAs as new biomarkers for detecting pancreatic cancer.
    Kishikawa T; Otsuka M; Ohno M; Yoshikawa T; Takata A; Koike K
    World J Gastroenterol; 2015 Jul; 21(28):8527-40. PubMed ID: 26229396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deep cfDNA fragment end profiling enables cancer detection.
    Zhitnyuk YV; Koval AP; Alferov AA; Shtykova YA; Mamedov IZ; Kushlinskii NE; Chudakov DM; Shcherbo DS
    Mol Cancer; 2022 Jan; 21(1):26. PubMed ID: 35062943
    [No Abstract]   [Full Text] [Related]  

  • 14. Exosomal biomarkers for cancer diagnosis and patient monitoring.
    Makler A; Asghar W
    Expert Rev Mol Diagn; 2020 Apr; 20(4):387-400. PubMed ID: 32067543
    [No Abstract]   [Full Text] [Related]  

  • 15. Circulating microRNAs as biomarkers in cancer diagnosis.
    Sohel MMH
    Life Sci; 2020 May; 248():117473. PubMed ID: 32114007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating cell-free nucleic acids as biomarkers in colorectal cancer screening and diagnosis - an update.
    Molnár B; Galamb O; Kalmár A; Barták BK; Nagy ZB; Tóth K; Tulassay Z; Igaz P; Dank M
    Expert Rev Mol Diagn; 2019 Jun; 19(6):477-498. PubMed ID: 31046485
    [No Abstract]   [Full Text] [Related]  

  • 17. Competitive learning suggests circulating miRNA profiles for cancers decades prior to diagnosis.
    Keller A; Fehlmann T; Backes C; Kern F; Gislefoss R; Langseth H; Rounge TB; Ludwig N; Meese E
    RNA Biol; 2020 Oct; 17(10):1416-1426. PubMed ID: 32456538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in circulating nucleic acids in oncology.
    Otandault A; Anker P; Al Amir Dache Z; Guillaumon V; Meddeb R; Pastor B; Pisareva E; Sanchez C; Tanos R; Tousch G; Schwarzenbach H; Thierry AR
    Ann Oncol; 2019 Mar; 30(3):374-384. PubMed ID: 30753271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating cell-free DNAs and miRNAs as promising non-invasive biomarkers for early detection of gastric cancer.
    Liu X; Chu KM
    Neoplasma; 2016; 63(1):1-9. PubMed ID: 26639229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical relevance of circulating cell-free microRNAs in ovarian cancer.
    Nakamura K; Sawada K; Yoshimura A; Kinose Y; Nakatsuka E; Kimura T
    Mol Cancer; 2016 Jun; 15(1):48. PubMed ID: 27343009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.